Literature DB >> 8390368

Effect of metoclopramide, ondansetron and granisetron on aldosterone secretion in man.

D K Sommers1, J R Snyman, M van Wyk.   

Abstract

The plasma aldosterone response following the administration of drugs with antagonist and agonist activity at Serotonin 3 and 4 (5-HT3&4) receptors has been examined in 9 healthy male volunteers receiving the following four treatments i.v. in a randomised, cross-over sequence: ondansetron 8 mg, granisetron 3 mg, metoclopramide 20 mg, and saline 20 ml. Metoclopramide significantly increased the mean plasma aldosterone level to 196% of basal level at 5 min. It rose to 234% at 15 min and remained at more than 185% of basal level for the duration of the experiment. The response to ondansetron and granisetron did not differ significantly from placebo. If dopamine antagonism is discounted, the results suggest that metoclopramide-induced aldosterone secretion results from its agonist activity at 5-HT4 receptors, although slow neuronal depolarization via an unidentified receptor remains a possibility. Antagonism at the 5-HT3 receptor plays no role, as the selective antagonist, granisetron, did not elicit a significant response. It seems unlikely that the 5-HT4 receptor is the second, low affinity binding site of ondansetron, unless it had no agonist activity at this receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390368     DOI: 10.1007/bf00316469

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

Review 1.  5-Hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders.

Authors:  B Costall; R J Naylor
Journal:  Scand J Gastroenterol       Date:  1990-08       Impact factor: 2.423

Review 2.  Molecular biology of 5-HT receptors.

Authors:  P R Hartig
Journal:  Trends Pharmacol Sci       Date:  1989-02       Impact factor: 14.819

Review 3.  Emerging differences between 5-HT3 receptor antagonists.

Authors:  H E Marr; P T Davey; A J Bartlett
Journal:  Anticancer Drugs       Date:  1991-12       Impact factor: 2.248

Review 4.  Novel enteric 5-HT4 receptors and gastrointestinal prokinetic action.

Authors:  M Tonini; C A Rizzi; L Manzo; L Onori
Journal:  Pharmacol Res       Date:  1991-07       Impact factor: 7.658

5.  Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine.

Authors:  E Rolandi; G Marchetti; R Franceschini; V Cicchetti; R Gianrossi; V Cantoni; T Barreca
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  The concept of selectivity in 5-HT receptor research.

Authors:  I van Wijngaarden; M T Tulp; W Soudijn
Journal:  Eur J Pharmacol       Date:  1990-06-12       Impact factor: 4.432

7.  Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).

Authors:  G J Sanger; D R Nelson
Journal:  Eur J Pharmacol       Date:  1989-01-10       Impact factor: 4.432

8.  The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons.

Authors:  A Dumuis; M Sebben; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

9.  Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924.

Authors:  G J Sanger
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

10.  Effects of enhancement and antagonism of 5-hydroxytryptamine activity on metoclopramide-induced aldosterone secretion in man.

Authors:  D K Sommers; E C Meyer; M van Wyk
Journal:  Res Exp Med (Berl)       Date:  1991
View more
  2 in total

1.  A serotonergic mechanism for the metoclopramide-induced increase in aldosterone level?

Authors:  C A Rizzi
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

2.  Effects of pretreatment with dexfenfluramine and fluoxetine on metoclopramide-induced aldosterone secretion in healthy volunteers.

Authors:  de K Sommers; J R Snyman; M van Wyk
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.